Modulation of anthracycline resistance in poor-risk acute myeloid leukemia (AML) with SDZ PSC-833: Results of a phase I/II multicenter study.

被引：0
|
作者：
List, AF
Karanes, C
Dorr, R
Spier, C
Grogan, T
Greer, J
Moore, J
Weinberger, J
Schiller, G
Dalton, W
Pearce, T
Litchman, M
机构：
[1] UNIV ARIZONA, TUCSON, AZ 85721 USA
[2] WAYNE STATE UNIV, DETROIT, MI 48202 USA
[3] VANDERBILT UNIV, NASHVILLE, TN 37240 USA
[4] DUKE UNIV, DURHAM, NC 27706 USA
[5] LOUISIANA STATE UNIV HLTH SCI CTR, SHREVEPORT, LA 71105 USA
[6] UNIV CALIF LOS ANGELES, LOS ANGELES, CA 90024 USA
[7] SANDOZ, E HANOVER, NJ USA
来源：
BLOOD | 1996年 / 88卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1156 / 1156
页数：1
相关论文
共 50 条
  • [21] Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia (vol 19, pg 1589, 2001)
    Dorr
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (09) : 2583 - 2583
  • [22] Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: Final induction results of cancer and leukemia group B study 9621
    Kolitz, JE
    George, SL
    Dodge, RK
    Hurd, DD
    Powell, BL
    Allen, SL
    Velez-Garcia, E
    Moore, JO
    Shea, TC
    Hoke, E
    Caligiuri, MA
    Vardiman, JW
    Bloomfield, CD
    Larson, RA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (21) : 4290 - 4301
  • [23] Phase I study of amonafide plus cytosine arabinoside (AraC) in patients with poor risk acute myeloid leukemia (AML).
    Allen, SL
    Kolitz, JE
    Lundberg, A
    Champagne, M
    Devost, S
    Dubon, R
    Drouin, M
    Boss, MA
    Grieshaber, CK
    Budman, DR
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 585S - 585S
  • [24] Risk-adapted induction therapy for de novo adult acute myeloid leukemia (AML): A prospective phase I-II study.
    Lioure, B
    Harousseau, JL
    Cahn, JY
    Witz, F
    Vilque, JP
    Ifrah, N
    Guyotat, D
    Guilhot, F
    Dreyfus, F
    Berthou, C
    Bergerat, JP
    [J]. BLOOD, 2000, 96 (11) : 325A - 325A
  • [25] A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia
    Bauer, KS
    Karp, JE
    Garimella, TS
    Wu, SL
    Tan, M
    Ross, DD
    [J]. LEUKEMIA RESEARCH, 2005, 29 (03) : 263 - 271
  • [26] A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients
    Hui-Jen Tsai
    Shih Sheng Jiang
    Wen-Chun Hung
    Gautam Borthakur
    Sheng-Fung Lin
    Naveen Pemmaraju
    Elias Jabbour
    John S. Bomalaski
    Ya-Ping Chen
    Hui-Hua Hsiao
    Ming-Chung Wang
    Ching-Yuan Kuo
    Hung Chang
    Su-Peng Yeh
    Jorge Cortes
    Li-Tzong Chen
    Tsai-Yun Chen
    [J]. Scientific Reports, 7
  • [27] A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients
    Tsai, Hui-Jen
    Jiang, Shih Sheng
    Hung, Wen-Chun
    Borthakur, Gautam
    Lin, Sheng-Fung
    Pemmaraju, Naveen
    Jabbour, Elias
    Bomalaski, John S.
    Chen, Ya-Ping
    Hsiao, Hui-Hua
    Wang, Ming-Chung
    Kuo, Ching-Yuan
    Chang, Hung
    Yeh, Su-Peng
    Cortes, Jorge
    Chen, Li-Tzong
    Chen, Tsai-Yun
    [J]. SCIENTIFIC REPORTS, 2017, 7
  • [28] Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia
    Sweet, Kendra
    Komrokji, Rami
    Padron, Eric
    Cubitt, Christopher L.
    Turner, Joel G.
    Zhou, Junmin
    List, Alan F.
    Sallman, David A.
    Dawson, Jana L.
    Sullivan, Daniel M.
    Chavez, Julio
    Shah, Bijal D.
    Lancet, Jeffrey E.
    [J]. CLINICAL CANCER RESEARCH, 2020, 26 (01) : 54 - 60
  • [29] A phase I study of induction chemotherapy for older patients (pts) with acute myeloid leukemia (AML) using ara-C (A), daunorubicin (D) and etoposide (E) with and without the MDR modulator PSC-833 (P): Cancer and leukemia group B (CALGB) study 9420.
    Lee, E
    George, S
    Caligiuri, M
    Dodge, R
    Smith, R
    Szatrowski, T
    Schiffer, C
    [J]. BLOOD, 1997, 90 (10) : 2256 - 2256
  • [30] Dose escalation studies of ara-c (A), daunorubicin (D) and etoposide (E) with and without multidrug resistance (MDR) modulation with PSC-833 (P) in untreated adults with acute myeloid leukemia (AML) < 60 years:: Final induction results of CALGB 9621.
    Kolitz, JE
    George, SL
    Dodge, RK
    Hoke, E
    Hurd, DD
    Powell, BL
    Velez-Garcia, E
    Caligiuri, MA
    Moore, JO
    Vardiman, JW
    Bloomfield, CD
    Larson, RA
    [J]. BLOOD, 2001, 98 (11) : 461A - 461A
12345